

REVIEW

Open Access



Renal perfusion pressure: role and implications in critical illness

Rakshit Panwar^{1,2*}, Bairbre McNicholas^{3,4}, J. Pedro Teixeira^{5,6} and Amit Kansal^{7,8}

Abstract

The pressure-flow relationship is fundamental to circulatory hemodynamics of any organ. In the kidney, renal perfusion pressure (RPP), defined as the gradient between mean arterial pressure and renal venous pressure or mean systemic filling pressure, serves as the principal driving pressure for renal blood flow (RBF). This concept recognizes that both arterial hypotension and venous congestion can reduce the pressure gradient for renal perfusion, potentially contributing to renal dysfunction or acute kidney injury (AKI). In health, whenever RPP fluctuates, the kidney autoregulates intrarenal vascular resistance to maintain stable RBF and glomerular filtration rate over a range of RPP. However, in critical illness, autoregulatory capacity may be impaired, and the degree of impairment can vary not only between patients but also within the same patient depending on the disease context or stage of illness. Therefore, during critical illness, inadequate RPP tends to overwhelm renal autoregulation capacity earlier than anticipated, leading to tissue hypoperfusion and increased risk of AKI. Relying on standard blood pressure targets to optimize RPP may not account for such inter- or intra-individual variations in autoregulation. Experimental models have shown that AKI can develop without overt macrocirculatory changes, implicating microcirculatory dysfunction as an important contributor too. Dynamic, multi-modal assessment of renal perfusion may offer a more precise approach to renal protection. Additionally, the focus of research has shifted towards providing new insights into individualized perfusion targets and refining RPP-guided strategies to prevent AKI among high-risk patients in ICU. The objective of this review is to describe the role of RPP, implications of dysregulated renal perfusion, approaches to monitoring renal perfusion, and potential therapies targeting RPP on the horizon for critically ill patients.

Keywords Renal perfusion pressure, Targets, Renal blood flow, acute kidney injury, Septic shock, Vasopressor therapy, Renal autoregulation, Renal microcirculation

*Correspondence:

Rakshit Panwar
rakshit.panwar@health.nsw.gov.au

¹Intensive Care Unit, John Hunter Hospital, Newcastle, Australia

²School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

³Intensive Care Unit, Galway University Hospital, Galway, Ireland

⁴University of Galway, Galway, Ireland

⁵Division of Nephrology, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA

⁶Center for Adult Critical Care, University of New Mexico Hospital, Albuquerque, NM, USA

⁷Department of Intensive Care Medicine, Ng Teng Fong General Hospital, National University Health System, Singapore, Singapore

⁸Department of Biomedical Informatics, National University of Singapore, Singapore, Singapore



© Crown 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Renovascular anatomy

The kidneys receive approximately 20–25% of the cardiac output - roughly 1 L per minute of blood flow (Fig. 1). Despite such high blood flow, overall oxygen extraction is relatively low (10% of oxygen delivery (DO_2)) compared to the heart or brain, because the vast majority of the high blood flow is used for filtration rather than metabolic activity [1]. The renal arterial system comprises macrocirculatory components, including the renal arteries and their branches, as well as the renal microcirculation, which includes two primary capillary networks, the glomerular capillaries and the peritubular capillaries, along with their associated arterioles [2, 3].

The nephrovascular unit consists of nephrons and their associated vasculature (glomerular and peritubular capillaries), integrating blood flow with tubular function. The arterial network supplying the nephrons resembles a rooted tree, branching hierarchically from the renal artery to the afferent arterioles, ensuring precise regulation of glomerular filtration and tubular reabsorption [4]. Afferent arterioles feed the glomerular capillaries, which are drained by efferent arterioles. These efferent arterioles give rise to peritubular capillaries surrounding the tubules, which, in the medulla, form the vasa recta. Glomerular capillaries mediate filtration, peritubular capillaries facilitate tubular reabsorption and secretion, and the vasa recta enable countercurrent exchange and arteriovenous oxygen shunting [5, 6]. The vasa recta also help establish the corticomedullary osmotic gradient essential for the urinary concentrating ability of the kidneys [7].

Glomeruli feed plasma filtrate into nephrons - the functional units of the kidney. There are approximately 1 million nephrons per kidney in humans; this number is reduced in hypertensive patients [8, 9]. The cortex of the kidney receives the majority of blood flow and has higher tissue oxygen concentration, whilst the outer medulla receives about half that flow and has a lower tissue oxygen concentration, making it vulnerable to hypoxia due to countercurrent exchange or arteriovenous shunting [6]. These structural features have important clinical implications, as they contribute to regional differences in susceptibility to ischemia, irreversible loss of nephrons following vascular occlusion, and heightened sensitivity of the medulla to hypoxic or ischemic injury [4].

Renal perfusion pressure and physiology of autoregulation

Renal perfusion pressure (RPP) is the effective pressure gradient driving renal blood flow (RBF), and is typically estimated as the difference between mean arterial pressure (MAP) and either intrarenal venous pressure or mean systemic filling pressure (MSFP) or central venous pressure (CVP) as a surrogate [10]. CVP reflects pressure in the thoracic vena cava near the right atrium and is influenced by multiple factors, including intrathoracic pressure, right heart function, and volume status. MSFP, in contrast, is a theoretical construct representing the pressure in the systemic circulation when there is no flow, reflecting the elastic recoil of the vasculature and stressed blood volume - effectively, the driving pressure




Fig. 1 Renal blood flow relative to other vital organs

Note: This figure illustrates the relative perfusion of key organs, highlighting the kidneys as having the highest arterial blood flow per unit tissue mass. Reprinted from the *Journal of the American College of Cardiology* [220], Vol. 74, Issue 9, Julio A. Chirinos, Patrick Segers, Timothy Hughes, Raymond Townsend, Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review, pp. 1237–1263, Copyright ©2019, with permission from Elsevier

for venous return [11]. While MSFP offers a more physiologically grounded basis for estimating the downstream component of RPP, it is difficult to measure directly in clinical settings. Surrogate equations (e.g. $MSFP = 0.96 \times CVP + 0.04 \times MAP + c \times CO$) have been proposed [12], however, this model assumes fixed weightings for the contribution of CVP and MAP, which may not reflect inter-individual variability in vascular tone or compliance, particularly in critical illness. Moreover, the fact that CVP itself is heavily weighted in this estimate reintroduces its limitations into the MSFP calculation. Estimation of MSFP using inspiratory hold-based methods or extrapolation from venous return curves remain largely experimental and have not been brought into routine clinical practice [13]. CVP is used as a surrogate for renal venous pressure, but it is likely that MAP- MSFP is a better representation, although technically challenging, of the true perfusion gradient across the kidney [10].

Factors influencing RPP include systemic arterial pressure, renal vascular resistance, venous congestion, neurohumoral regulation, and local metabolic signals. Normal renal function requires tubular flow to remain within a narrow physiological range, and deviation from this range can compromise nephron function. The kidney maintains RBF and glomerular filtration rate (GFR) across a wide range of arterial pressures through autoregulation (Fig. 2) - primarily via an enhanced myogenic response in renal arterioles, contributing ~50% of autoregulation, and tubuloglomerular feedback (TGF), which accounts for ~35%, with other less well understood mechanisms accounting for the rest [14–17].

All vascular beds exhibit some degree of autoregulatory response to changes in perfusion, usually mediated by a myogenic mechanism, in which the mechanical forces exerted upon the walls of an arteriole in the setting of increased perfusion trigger contraction of vascular smooth muscle cells [16]. The myogenic response




Fig. 2 Autoregulation in usual health

Note: This schematic diagram illustrates the pressure-flow relationship of renal blood flow (RBF) with renal arterial pressure under normal conditions. Under physiological conditions, tissues autoregulate their blood flow to align with metabolic demands, maintaining relatively constant perfusion despite fluctuations in perfusion pressure - approximately within a range of 60 to 150 mm Hg. When pressure drops below the lower limit of autoregulatory threshold, flow becomes pressure-dependent rather than demand-driven, heightening the risk of ischemia in metabolically active regions. In chronic hypertension, however, adaptive changes such as microvascular remodeling, capillary rarefaction, and increased vascular resistance shift the autoregulatory curve rightward. As a result, the lower limit of effective autoregulation rises, making 60 mm Hg an inadequate perfusion pressure for the kidneys and other vital organs in these patients. While this shift is well recognized in theory, its integration into routine clinical decision-making remains inconsistent

involves rapid adjustments in afferent arteriole tone - vasoconstriction or dilation - within seconds of local pressure changes [14]. TGF, a kidney-specific negative feedback system, operates on a slower timescale of approximately 30 s. It regulates single-nephron GFR based on chloride concentrations sensed at the macula densa via the apical Na-K-2Cl (NKCC2) cotransporter, the pharmacologic target of furosemide and other loop diuretics [18]. The macula densa detects changes in sodium delivery through chloride sensing channel and then modulates afferent and efferent arteriolar tone to stabilise GFR. This feedback loop also effects renin release and adjusts arteriolar tone through paracrine mediators such as adenosine, nitric oxide, and prostaglandins [18, 19], tying tubular flow to vascular resistance [20] and ultimately restoring RBF back towards its physiological set point [19].

In addition to these autoregulatory mechanisms that are largely intrinsic to the kidney, RBF is highly regulated by a variety of additional autocrine, paracrine, and hormonal factors. These mediators can be broadly categorized as vasodilatory or vasoconstrictive. Vasodilatory substances include nitric oxide (NO) and locally-produced prostaglandins (e.g., prostaglandin E_2 and prostacyclin) that play a role in maintaining RBF in the setting of hypoperfusion states [21, 22]. Vasoconstrictive factors include renal sympathetic nerve activity as well as circulating norepinephrine, angiotensin II, endothelins, vasopressin, and vasoconstrictive prostaglandins (e.g., thromboxane) [21, 22].

Importantly when considering the impact of these vasoactive substances on RBF and GFR, the primary site of activity - afferent versus efferent arteriole - is vitally important. Vasoconstrictors that act primarily upon the afferent arteriole (e.g., sympathetic nerves/ norepinephrine or endothelin) will tend to reduce both RBF and GFR, whereas vasodilators that act primarily upon the afferent arteriole (e.g., nitric oxide and vasodilatory prostaglandins) will tend to increase both parameters [23]. In contrast, vasoactive agents that act primarily upon the efferent arteriole will have opposing effects on RBF and GFR. For example, vasoconstrictors such as angiotensin II and vasopressin will tend to decrease RBF but, as they constrict outflow from the glomerular capillaries, tend to maintain glomerular pressure and GFR [23, 24].

However, while these local effects influence how these vasoactive agents tend to modulate RBF and GFR, the overall effect of exogenous vasoconstrictors or vasodilators will also depend on their systemic effects. For example, though norepinephrine tends to reduce RBF when infused to subjects with normal hemodynamic status or hypovolemia, it tends to maintain or even increase RBF when given in hyperdynamic septic shock by correcting pathologic vasodilation and/or restoring RPP,

thereby potentially improving kidney function [25–31]. Conversely, the direct effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers would tend to increase RBF, but if administered to patients with pre-existing hypotension or hypovolemia the resulting decrease in RPP could reduce RBF.

Pathophysiology of renal hypoperfusion

In the early stages of reduced RBF with corresponding drop in GFR, the kidney enters a state of 'self-preservation' characterized by permissive azotemia [32]. This adaptive response may be protective: it decreases the delivery of inflammatory mediators into the tubules [33] and reduces the tubular solute load and subsequent reabsorption, thereby lowering metabolic strain by reducing tubular oxygen demand [34].

If the pathological insult persists, hypoperfusion ensues once RPP falls below the lower autoregulatory threshold - or even within a normal range if autoregulation is impaired as commonly seen in critical illness (Fig. 3) - resulting in reduced DO_2 and renal tubular ischemia [35]. Likewise, inadequate transglomerular pressure gradient, due to increased afferent arteriolar resistance, efferent arteriolar dilation, or both, further reduces GFR. These changes collectively impair adenosine triphosphate delivery to metabolically active tubular epithelial cells, exacerbating tubular injury [36].

Additionally, reduced RBF also invokes a mechanism of increasing the filtration fraction (FF) to maintain GFR. The FF represents the amount of RBF being filtered in the Bowman's space ($FF = GFR/RBF$) [37]. A higher FF increases proximal tubular sodium and water reabsorption, as tubular transport is highly load-dependent [38]. There is a close linear correlation between GFR, sodium reabsorption, and oxygen consumption (VO_2), implying that increased tubular workload for reabsorption requires higher tubular O_2 consumption [39]. Notably, at baseline, 70–80% of renal VO_2 supports active sodium reabsorption [40]. In states of hypoperfusion, this demand-supply mismatch aggravates tubular damage.

Macro- and micro-circulation

Large epidemiological studies report that 25–88% of patients with septic AKI require vasoactive support at the time of diagnosis, suggesting that macrocirculatory abnormalities are common in patients with human septic AKI [41–44]. Phase-contrast MRI studies performed within 48 h of ICU admission have demonstrated reduced renal blood flow in septic AKI, indicating that macrocirculatory compromise may occur early [45]. However, some experimental models have shown that AKI can develop without overt macrocirculatory changes, implicating microcirculatory dysfunction as an important contributor too [46]. Notably, these animal studies often




Fig. 3 Vulnerability of renal autoregulatory capacity during critical illness

Note: This schematic diagram illustrates the pressure-flow relationship in states of impaired autoregulation such as critical illness or in patients with comorbidities. In health, intact autoregulation ensures renal blood flow (RBF) remains constant despite fluctuations in renal perfusion pressure (RPP). However, in critical illness, autoregulation may be impaired or lost, resulting in a direct pressure-flow dependency as shown. Consequently, RBF may be significantly reduced at RPP values that are conventionally considered adequate. Autoregulatory capacity, when compromised, is associated with increased morbidity and mortality (bold red line). This illustrates the potential inadequacy of a fixed RPP threshold and the importance of individualized targets.

avoided or mitigated hypotension through early fluid or vasopressor therapy. In contrast, in clinical practice, sepsis is often not recognised until after hemodynamic compromise or organ dysfunction is evident. Several human and animal studies have demonstrated that interventions aimed at improving macrocirculatory parameters, particularly vasopressors, may favourably influence the renal microcirculation [25, 47–49]. Therefore, a reasonable interpretation is that septic AKI arises from a complex interplay between macro- and micro-circulatory factors. While sepsis accounts for a substantial proportion of AKI in the ICU, other causes such as surgery, shock states, drug toxicity, or hepatorenal or cardiorenal syndrome [50–52] are also common, and the role of microcirculatory dysfunction in these settings remains less well characterised [53].

Renal interstitial pressure

An increase in renal venous pressure will be conducted backwards and lead to renal parenchymal congestion within the non-distensible renal capsule. Renal interstitial pressure will also be elevated with tubular injury, which causes significant filtrate leakage and intra-renal inflammation due to disruption of tubular tight junctions and tubular obstruction [54, 55]. Studies suggest the role of lipopolysaccharide-induced disruption of the tight junctions in proximal tubules, resulting in filtrate leakage from the proximal tubular lumen into the interstitium in septic AKI [56]. Tubular injury also diminishes reabsorptive efficiency and contributes to luminal obstruction, further elevating interstitial pressure and impairing renal function. These processes create a vicious cycle: tight junction disruption leads to more filtrate escape, amplifying interstitial pressure and worsening tissue injury.

Intra-abdominal hypertension

Extra-renal stress due to increased intra-abdominal pressure (IAP) leads to decreased RBF, GFR, tubular function, and urine output [57]. Normal IAP is approximately 5–7 mmHg, whereas intra-abdominal hypertension is defined as sustained IAP of ≥ 12 mmHg, with abdominal compartment syndrome defined as intra-abdominal hypertension leading to new organ dysfunction (usually with IAP > 20 mmHg) [57, 58]. As IAP rises above central venous pressure (CVP) and renal venous pressure, it is transmitted to renal veins, effectively becoming the downstream pressure for renal perfusion (i.e., $RPP = MAP - IAP$) [59]. In fact, the kidneys are so susceptible to increased IAP that abdominal compartment syndrome is considered unlikely in the absence of oliguria [51]. While abdominal compartment syndrome is characteristically described in patients with acute abdominal pathology or after major abdominal surgery, recent data suggest that intra-abdominal hypertension plays a role in the pathogenesis of hepatorenal syndrome and AKI in general in patients with liver disease. Multiple studies have found high rates of intra-abdominal hypertension in patients with cirrhosis, especially among the critically ill [60–62].

Urinary tract obstruction

Urinary obstruction initially triggers a compensatory increase in RBF, likely mediated by kidney-derived prostaglandin E_2 , to preserve GFR. This response is more pronounced in bilateral than in unilateral obstruction [63]. However, within hours, RBF begins to decline while intratubular pressure continues to rise. As RBF progressively diminishes, GFR falls, and intrarenal blood flow redistributes from the cortex to the medulla. Sustained obstruction under these conditions leads to acute tubular injury and, if unrelieved, can result in irreversible renal damage [36].

Impact of renal replacement therapy

While lifesaving, renal replacement therapy (RRT) may itself contribute to AKI [64]. It can reduce GFR and cause tubular stress, potentially leading to worsening oliguria and delayed renal recovery [65]. These effects appear to be mediated by hypoperfusion, particularly due to excessive ultrafiltration - either from higher intensity of RRT or faster net ultrafiltration rates [66, 67]. Additionally, multiple other RRT-related factors may exacerbate renal insult [64, 68]. These include rapid plasma osmolality shifts [69], dialysate temperature if higher than patient's core temperature [70], dialyzer bio-incompatibility [71], unintended clearance of beneficial substances such as vasoactive drugs [72], and reduction in myocardial blood flow with transient myocardial stunning [73–75].

Monitoring techniques

Challenges in monitoring renal perfusion

At the macrocirculatory level, estimating RPP - particularly if derived using CVP - may be inaccurate, as it may not account for elevated IAP or the presence of intracapillary or renal interstitial hypertension. These conditions can contribute to renal congestion and reduce effective RPP, particularly in patients receiving mechanical ventilation or those with abdominal pathology or with significant fluid overload. At the microcirculatory level, monitoring renal perfusion is complicated by the kidney's heterogeneous vasculature. Presence of several different vascular beds in the glomerular, juxtaglomerular, and medullary (inner and outer) circulation, each with associated independent regulatory mechanisms, results in significant variability in perfusion response [7, 76]. Such heterogeneity makes it difficult to extrapolate findings from the microcirculation of one region to the entire kidney. Moreover, capillary density within the kidneys varies from individual to individual and can dynamically change during the course of an illness. A decrease in capillary density either due to disease progression or inflammation can elevate intrarenal vascular resistance, altering microcirculatory hemodynamics and complicating an accurate assessment of renal perfusion [76].

Multi-modal monitoring of renal perfusion may be more effective in early detection of renal malperfusion among critically ill patients. As reviewed below, other monitoring tools that have recently emerged are renal biomarkers, renal Doppler ultrasound, contrast-enhanced renal ultrasound, microcirculation monitoring, tissue oxygenation monitoring, and assessment of intrarenal pressure. These techniques may offer insights into adequacy of renal perfusion in a more dynamic manner. However, most of these tools are still under evaluation and are yet to be widely adopted in clinical practice.

Novel renal biomarkers

Biomarkers can potentially help improve early detection of renal stress or sub-clinical AKI beyond traditional markers such as serum creatinine or urine output, however no biomarker alone currently provides a direct assessment of renal perfusion. Circulating renin levels, with a short half-life of ~ 10 min and a prompt trigger response to hypotension, is well suited for dynamic monitoring and has emerged as a promising marker of renal perfusion among critically ill patients [77]. Multiple studies show that renin has strong associations with both mortality [78, 79] and new adverse kidney events [80, 81] even outperforming lactate in predicting mortality in hypotensive ICU patients [82, 83]. In addition, high renin levels may be able to identify patients more likely to benefit from exogenous angiotensin II [84], underscoring its potential as a tool to guide therapy. Work is ongoing on

developing a point-of-care renin assay, which may accelerate its adoption in clinical settings.

Several other biomarkers have emerged as sensitive indicators of renal tubular stress from suboptimal perfusion. One of the most extensively studied biomarkers of kidney damage is neutrophil gelatinase-associated lipocalin (NGAL), which is a member of the lipocalin superfamily of proteins and is upregulated in renal tubular and inflammatory cells in response to injury. It has emerged as an early, sensitive, and noninvasive urinary biomarker of both ischemic and nephrotoxic AKI [85]. NGAL, measured either in serum or urine, can potentially predict AKI 24–48 h before the diagnosis of creatinine-based AKI and to detect subclinical AKI (i.e., NGAL-positive but creatinine-negative), which is associated with subsequent need for RRT or death [86–89]. Perhaps two of the most validated biomarkers are urinary tissue-inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7), which are released by tubular cells in response to ischemia or injury, and their product $[\text{TIMP-2}] \times [\text{IGFBP7}]$ has been shown to be an accurate predictor of all-cause AKI [90, 91]. Importantly, biomarker $([\text{TIMP-2}] \times [\text{IGFBP7}])$ triggered management, focused on optimizing volume status, maintaining perfusion pressure, and discontinuing nephrotoxic agents, has shown clinical benefit in high risk post-surgical ICU patients in randomized trials [92, 93]. Another biomarker, kidney injury molecule-1 (KIM-1), an immunoglobulin superfamily cell-surface protein, is not normally detectable in health, but is dramatically upregulated in an ischemic kidney in the surviving proximal epithelial cells [94, 95]. Overall, while no biomarker alone currently provides a direct assessment of renal perfusion, combining these biomarkers with clinical risk scores seems promising for early detection of renal malperfusion or risk stratification of AKI and treatment [96–98].

Renal ultrasound

Intrarenal Doppler ultrasound is gaining attention for evaluating renal perfusion and congestion in critically ill patients. One of the most widely used indicators is renal resistive index (RRI), which is obtained via Doppler ultrasound of the intrarenal arteries and calculated as the difference between the peak systolic velocity (V_{systole}) and end-diastolic velocity (V_{diastole}) divided by the peak systolic velocity (i.e., $\text{RRI} = [V_{\text{systole}} - V_{\text{diastole}}] / V_{\text{systole}}$). RRI is primarily influenced by pulse pressure and renal capillary wedge pressure, and provides a hemodynamic window to renal perfusion [99, 100]. It is a potentially reliable predictor of overall survival [101]. However, the relationship between RRI and renal vascular resistance is complex and influenced by a variety of factors [102], with one multi-centre study of 371 ICU patients demonstrating that RRI,

though statistically associated with development of AKI, performed relatively poorly in the prediction of persistent AKI or need for RRT [103]. As such, additional studies are needed to better delineate and validate the role of RRI in the evaluation of patients at risk of AKI in the ICU.

On the venous side, intrarenal vein Doppler can be used to assess intrarenal venous flow (IRVF) patterns. In the setting of renal venous congestion, the normal pattern of continuous IRVF is replaced by a discontinuous flow, an effect which can be quantified using the renal venous stasis index (RVSI). Discontinuous IRVF patterns or elevated RVSI are indicators of congestion or reduced intrarenal compliance that may be useful in limiting fluid resuscitation to avoid renal parenchymal congestion [104, 105]. The combination of intrarenal venous Doppler with hepatic vein and portal vein Doppler has been incorporated into a generalized assessment of intraabdominal organ congestion called the venous excess ultrasound (VExUS) score, which has gained significant traction as a method to guide fluid management in patients with heart failure or general critical illness [106–109].

Another monitoring technique is contrast-enhanced ultrasound (CEUS), which, in contrast to Doppler ultrasound, can be used to evaluate the microcirculation and has been used to assess tissue perfusion for several organs. CEUS quantitatively assesses alterations in renal microcirculation in real time by using highly echogenic inert microbubbles of similar size as red blood cells to map areas of perfusion [110]. The quantitative parameters obtained through CEUS are strongly correlated with RBF, which may facilitate real-time monitoring of renal microcirculatory perfusion, enabling individualized hemodynamic therapy [111]. However, data thus far on the use of CEUS in the ICU, though showing some promise in predicting the prognosis of AKI, are limited to small single-centre studies [112–114]. In addition, CEUS is complex, with a variety of factors and artefacts able to influence CEUS parameters, with some studies suggesting significant measurement variability and, for some parameters, poor reproducibility [112, 114]. Additional data are needed to better define and validate the utility of CEUS in the ICU.

Tissue oxygenation and microcirculation monitoring

Near-infrared spectroscopy (NIRS) is a potentially useful modality to measure renal tissue oxygen saturation (rSO_2) in real-time by detecting the regional balance between oxygenated and deoxygenated hemoglobin within a local tissue area [115, 116]. This allows dynamic monitoring of rSO_2 over time and such trajectory analysis can better capture the risk of AKI compared to static thresholds [117]. Another promising tool that was first developed decades ago but has recently re-emerged for

monitoring renal medullary oxygenation is continuous measurement of bladder urinary oxygen tension (PuO_2), which may be considered as a window into renal medullary health [110, 118, 119], but data to support its use remain limited to animal studies and small single-centre human studies [120–122]. Currently, microcirculation monitoring is an intense focus of research but validated bed-side tools are lacking [76].

Dynamic monitoring of renal autoregulation

Pressure-flow relationship in renal vasculature can be assessed dynamically by tracking changes in the measures of renal perfusion corresponding to spontaneous or induced changes in RPP [123]. As stated earlier, the autoregulatory mechanisms may be impaired or shifted in critical illness, particularly in presence of pre-existing comorbidities, making standard MAP targets less reliable to avoid malperfusion [124]. Dynamic monitoring of renal autoregulation threshold may hold some advantages in guiding towards an optimal target MAP rather than the current practice using empirically chosen targets. Optimizing renal perfusion may benefit other organs too. One study showed that the magnitude-duration of MAP below the lower autoregulation limit of cerebral blood flow was independently associated with the risk of new AKI [125]. This suggests a similar concept where the duration and degree to which RPP remains under the lower limit of renal autoregulation threshold may also be associated with AKI. Despite these promising insights, real-time assessment of renal autoregulation remains largely experimental and standardized clinical tools for bedside use are still lacking [123].

Monitoring for intra-abdominal hypertension

Emerging techniques for non-invasive or minimally invasive continuous IAP monitoring are under investigation. A novel bladder pressure transduction system connected to a fluid-filled Foley catheter has shown promising results in clinical validation studies, demonstrating accurate and continuous IAP measurement without need for repeated manual readings [126]. Such technologies may allow earlier recognition and management of intra-abdominal hypertension in at-risk ICU patients.

Therapeutic considerations

The key therapeutic focus in preserving renal function or facilitating renal recovery is the maintenance of macrovascular renal perfusion through attention to components of RPP - renal arterial blood pressure (upstream pressure), renal venous pressure (downstream pressure), intrarenal pressure (precipitated by tubular leakage; tubular obstruction; intra-renal inflammation, e.g., due to sepsis and/ or nephrotoxins; and intra-abdominal hypertension), and their dynamic interplay (Fig. 4). As we

discuss later, another potential therapeutic target under investigation is the complex cascade of microvascular dysfunction and cellular injury impacting aspects on molecular and microanatomical level - impaired microcirculation, inflammation, immune dysregulation, and oxidative injury.

Renal arterial blood pressure

Effective renal perfusion depends on maintaining sufficient forward flow and circulating volume. In the early stages of shock, timely restoration of cardiac output through judicious fluid resuscitation and prompt vasopressor initiation is essential. Observational studies suggest that lower MAP targets are associated with poorer renal outcomes in critically ill patients [127]. However, results from previous RCTs [128–131] evaluating different blood pressure targets in critically illness or peri-operative settings have been inconsistent. This may be explained by varied methodologies, patient populations, geographic settings, and the limitations of a one-size-fits-all approach associated with utilizing uniform MAP targets [132]. There is growing recognition that relative hypotension may represent an important target for hemodynamic optimization [133, 134]. However, aside from a few small pilot trials [135, 136] and an RCT conducted in non-ICU population [137], high-quality evidence is lacking to guide optimal strategies for individualizing RPP in ICU patients with shock. RPP or mean perfusion pressure (MPP), as a close surrogate, is increasingly regarded as a reliable marker compared to MAP or CVP alone for predicting risk of new-onset AKI [138–140]. In critically ill patients, reduced MPP, larger MPP deficits, and more time spent with a MPP deficit >20% relative to baseline have been linked to a higher risk of developing AKI [139–143]. In contrast, a retrospective cohort study in cardiac surgery patients reported no association between MPP deficit and AKI progression [144]. Differences in patient populations, vasopressor exposure, MPP assessment periods, confounders considered in multivariable analyses, definitions for AKI onset, and time windows for AKI progression, including underlying pathophysiology, could account for this discrepancy. Increasingly, focus has shifted toward evaluating individualized MAP targets tailored to patients' pre-illness blood pressure, as such an approach may be associated with improved outcomes [135, 141–143]. While promising, this concept remains unexplored in large trials, though a multicenter RCT is currently underway (NCT05850962).

Fluid management while avoiding overload

Effective fluid management plays a pivotal role in renal perfusion. Elevated CVP, a surrogate for renal venous pressure, has been independently associated with increased AKI risk, with lower CVP levels (below 8




Fig. 4 Therapeutic approaches for optimizing renal hemodynamics in critical illness

Note: This diagram outlines key modifiable factors influencing renal perfusion and therapeutic strategies targeting upstream (arterial), downstream (venous), and intrarenal pressures, alongside interventions addressing systemic, cardiac, and intra-abdominal contributors to help optimize renal hemodynamics

Ang-(1-7): angiotensin-(1-7); Ang-2: angiotensin II; CO: cardiac output; MAP: mean arterial blood pressure; RPP: renal perfusion pressure; RBF: renal blood flow

mmHg) correlating with better renal outcomes [139, 145]. Liberal fluid administration may worsen AKI risk by causing renal congestion and interstitial edema and impairing microvascular oxygen delivery [146–148]. Importantly, however, thus far RCTs evaluating protocolized fluid restriction in critically ill patients have had largely mixed outcomes. These trials suggest that fluid restriction is safe although without any mortality benefit in septic shock. Such strategies may reduce the duration of mechanical ventilation in patients with acute respiratory distress syndrome, however may increase the risk of AKI in major abdominal surgery [149–152]. Importantly, while most experts agree that early aggressive fluid resuscitation remains appropriate for patients with septic shock, subsequent caution with fluids is prudent to mitigate harms associated with volume overload [51, 153]. However, the optimal timing of transition between these two approaches remains to be precisely defined. Additional multicentre trials of fluid restriction in sepsis are ongoing (NCT04569942, NCT05179499).

The composition of fluids may also matter, as chloride-rich solutions can impair renal perfusion through vasoconstriction and altered TGF [154, 155]. Though large RCTs [156–158] have yielded somewhat mixed results and the effect size appears small, a recent Bayesian

meta-analysis [159] concluded that there is a high probability that use of balanced crystalloids in critical illness reduces mortality.

Vasoactive agents

Following initial volume resuscitation and restoration of adequate volume state, further improvement in renal perfusion in shock states generally requires vasopressor support [160]. Comparative RCTs [161–164] have shown that while overall clinical outcomes may be similar, vasopressin instead of or in addition to norepinephrine seems to be associated with better renal function preservation than use of norepinephrine alone in select high-risk patients.

The potential renal benefit of vasopressin may stem from its minimal vasoconstrictive effect on renal afferent arterioles and preferential vasoconstriction of efferent arterioles, thus maintaining glomerular pressure and GFR in the setting of compromised renal perfusion. As outlined in further detail below, the newer vasoconstrictor angiotensin II also preferentially acts on the efferent arteriole and therefore may also be useful to maintain kidney function in patients with shock, though thus far human studies to support this possible benefit are limited to post hoc analyses of trial data [165, 166]. Though

typically attributed to their differential effects on afferent vs. efferent arteriolar vasoconstriction, animal studies suggest that the renal benefits of vasopressin and angiotensin II could be mediated by differential effects on renal medullary perfusion and oxygenation [167, 168].

Specifically, the single-centre VANCS trial suggested a beneficial effect of vasopressin on the incidence of AKI in patients with vasoplegia after cardiac surgery [164], but this finding has yet to be validated in multicentre trials. In septic shock, secondary renal outcomes favouring vasopressin were observed in both the VASST and VANISH RCTs [162, 163], but the primary outcomes of each study, namely mortality and days free of stage 3 AKI, respectively, were neutral. A subsequent individual patient data meta-analysis showed that vasopressin was associated with reduced need for renal RRT [169], but the finding was not robust to sensitivity analyses and the result was primarily driven by the VANISH trial [164], in which RRT use was reduced in non-survivors but not in survivors. Additionally, observational data suggest that outcomes with vasopressin may vary based on timing and patient selection, with worse outcomes observed at higher doses and among patients with elevated lactate [170].

Likewise, the renal benefits of vasopressin and angiotensin II have been suggested by a recent meta-analysis evaluating the effects of non-adrenergic vasopressors in septic shock and post-operative vasoplegia. This meta-analysis found that, in an effect largely driven by vasopressin and angiotensin II, non-adrenergic agents were associated with decreased need for RRT [171]. Interestingly, several RCTs on vasopressin and angiotensin II predate the publication of the recent series of RCTs on the timing of initiation of RRT which collectively have shown no benefit to routine early use of RRT [65, 172, 173]. Therefore, future trials in the setting of modern RRT prescribing practices are required to validate such a benefit. Importantly, RCTs of systemic renal vasodilators like fenoldopam, natriuretic peptides, or levosimendan have not shown clinical benefit in terms of improving RBE, and have failed to reduce AKI incidence or mortality, despite plausible physiological mechanisms [174–176].

Reducing renal interstitial pressure

Another important target for optimizing RPP is managing renal interstitial pressure. Beyond judicious fluid therapy, a key strategy is active decongestion using diuretics or ultrafiltration. Additional measures include optimizing right heart function (e.g., by reducing pulmonary hypertension) and alleviating pericardial, intra-thoracic, or intra-abdominal pressures through drainage when necessary. Blood purification techniques using adsorption filters aimed at improving renal perfusion by reducing systemic inflammation are under investigation.

In one single-center retrospective study, use of the oXiris® hemofilter was associated with improved renal perfusion parameters based on ultrasound imaging, although clinical outcomes were no different in the treated and untreated groups and conclusive evidence to support this or other blood purification techniques remains lacking [177]. Early and targeted management of the underlying cause of AKI may also reduce intra-renal inflammation and support recovery. Elevated IAP can exacerbate renal interstitial pressure and impair RPP. Prompt recognition of intra-abdominal hypertension and timely interventions, such as fluid removal, bowel decompression, abdominal drainage, or surgical decompression, may improve renal perfusion and clinical outcomes [57]. Similarly, relieving urinary tract obstruction is critical for reducing intratubular pressure, restoring RBF distribution, and preventing acute tubular injury.

Countering inflammatory mediators

Inflammatory pathways, particularly in contexts of gram-negative sepsis, ischemia-reperfusion injury, or malignancy, can play a major role in the progression of AKI. These insults can trigger the release of pro-inflammatory cytokines and chemokines, which in turn activate dysregulated immune cell populations including neutrophils, macrophages, and natural killer cells [178]. While these mechanisms are well described in preclinical models, robust human evidence remains limited. In the STOP-AKI and REVIVAL RCTs, despite secondary outcomes suggesting benefit, treatment with human recombinant alkaline phosphatase failed to significantly improve the primary trial outcomes of kidney function and 28-day mortality, respectively, in critically ill patients with sepsis-associated AKI [179, 180]. Extracorporeal blood purification techniques aimed at removing circulating inflammatory mediators remain an area of active investigation, but definitive clinical benefit has yet to be demonstrated.

Renal replacement therapy

In view of its potential contribution to renal injury, recent studies have focused on defining safer practices in RRT prescription. Comparative RCTs of intermittent versus continuous RRT modalities have yielded inconsistent results in terms of survival or kidney recovery [181, 182]. Regarding continuous RRT, an individual patient data meta-analysis suggests that higher intensity RRT (prescribed dose higher than 20–25 mL/kg/h) can delay renal recovery, and should therefore be avoided in most patients [183]. Additionally, there is some evidence suggesting that higher net ultrafiltration rate (exceeding 1.75 mL/kg/h) may also delay renal recovery and perhaps should be used with caution [184] with the possible exception of cases of overt severe volume overload [185].

These concerns may be particularly relevant in critically ill patients with acute-on-chronic kidney disease [186].

Antioxidants

Oxidative stress, largely mediated by free oxygen radicals, may also contribute to renal injury under similar pathological conditions, including contrast exposure and chemotherapy. Antioxidant agents such as alpha-lipoic acid, selenium, sodium-2-mercaptoethane sulphonate (MESNA), and curcumin are some potential therapies that directly target free radicals. Despite promising animal studies, human data remains ambiguous or lacking. In the SUSTAIN CSX RCT, high-dose intravenous sodium selenite demonstrated no improvement in postoperative organ dysfunction or mortality in high-risk cardiac surgery patients [187]. Likewise, on the basis of observational studies, the antioxidant vitamin C was felt to have potential as a treatment in sepsis, but subsequent multicenter trials have shown no benefit or signals for harm [188–190].

Role of intravenous amino acids

Intravenous amino acid (L-Alanyl-Glutamine, L-amino acids, L-glutamic acids, peri-operative Custodiol® solution) have been investigated for their potential renoprotective effects through recruitment of renal functional reserve. Proposed mechanisms of action include increased renal perfusion, improved renal oxygenation, and increased GFR, which are likely achieved via decreased afferent arteriolar resistance, increased renal unit plasma flow, decreased TGF, and upregulated cortical nitric oxide synthase activity [191–194]. The PROTECTION RCT found that infusion of a balanced amino acid mixture reduced AKI incidence in patients undergoing cardiac surgery [195]. However, it remains uncertain whether this benefit reflects true renal protection at the tubular level, or only a functional improvement in perfusion, or both [196]. Two recent systematic reviews and meta-analyses, each including over 4500 patients surgical patients (although heavily weighted by the PROTECTION RCT), suggested that intravenous amino acids reduced the incidence of postoperative AKI and increased urine output, in patients at high risk of AKI, particularly after cardiac and major vascular surgery, but neither found a beneficial effect on the rate of RRT use or mortality [197, 198]. Moreover, the only RCT in critically ill ICU patients showed no significant benefit even with regards with AKI [199].

Restoring microvascular circulation

Beyond macrovascular flow disturbances, perturbations in renal microcirculation can also play a critical role in the development of AKI [200]. Emerging therapies are exploring ways to mitigate the downstream effects of

microvascular dysfunction and cellular injury in AKI. Targets include impaired microcirculation (e.g., angiotensin II, adenosine receptor antagonists), inflammation (e.g., alkaline phosphatase, sphingosine-1-phosphate analogues, dipeptidyl peptidase-3 inhibitors), immune dysregulation, oxidative stress (e.g., antioxidants such as alpha-lipoic acid, curcumin, Na-2-MCE, propofol, selenium), and transcriptional pathways modulated by genetic regulators such as 5INP [33, 201, 202].

Novel agents such as angiotensin II and adenosine receptor antagonists are being investigated for their ability to modulate microvascular tone and restore renal perfusion. Angiotensin II regulates the release of aldosterone and vasopressin and, through both these mediators and direct effects on the kidney, plays a key role in maintaining sodium and water homeostasis [203, 204]. During sepsis and inflammation, downregulation of angiotensin I type of angiotensin receptors and relative deficiency of angiotensin II have been observed, which may compromise renal perfusion [205]. Exogenous angiotensin II has been shown to maintain tissue perfusion and organ function in both animal and human studies of septic shock, although additional trials are needed to confirm its clinical utility [206, 207]. Another experimental therapy is Angiotensin 1–7, a Mas receptor agonist, and a major effector molecule of the alternative renin-angiotensin system which can modulate oxidative stress, inflammation, and endothelial injury [208]. In animal models of renal ischemia, activation of the alternative renin-angiotensin system, via administration of exogenous angiotensin 1–7 or an angiotensin II type 2 receptor agonist, mitigated oxidative stress and renal inflammation, alleviating ischemia-reperfusion induced kidney injury [209, 210].

Adenosine is another key mediator of renal microvascular tone. In response to hypoxia or increased tubular sodium chloride delivery, adenosine induces afferent arteriole vasoconstriction, thereby reducing GFR [211]. This mechanism can be inhibited by adenosine receptor antagonists, including nonselective agents like theophylline and aminophylline, and selective A1 receptor blockers such as rollophylline. However, clinical studies so far have yielded limited clinical benefit and conflicting results [212–214].

Taken together, although these microvascular interventions hold physiological promise, their clinical utility remains uncertain. As stated above, evidence from animal models and human observational studies suggests that early fluid resuscitation and appropriate vasopressor therapy may help mitigate sepsis-induced microcirculatory dysfunction and may beneficially modulate the microcirculation [25, 47–49]. These findings also highlight that microcirculatory flow is influenced by macro-hemodynamic variables such as elevated CVP and

reduced MAP, indicating a dynamic interplay between the macrocirculation and microcirculation [25, 47–49, 215, 216]. Thus, the notion that AKI in sepsis is driven solely by either microcirculatory or macrocirculatory dysfunction is likely a false dichotomy. Nonetheless, in the absence of clinically validated tools to assess or treat microcirculatory dysfunction at the bedside, macro-circulatory optimization remains central to the prevention and management of AKI in critically ill patients [92, 93, 217–219].

Future directions

Despite substantial progress in understanding of renal hemodynamics, there are significant knowledge gaps and research opportunities. RPP or MPP (as a close surrogate) is increasingly regarded as a reliable marker compared to MAP or CVP alone. These macrocirculatory surrogate markers, however, may not correlate well with renal microcirculatory perfusion, which is a function of several other factors. Future research must address key gaps in our understanding of microvascular dynamics and renal autoregulation capacity. Rather than static or uniform MAP targets often pursued in real-world practice, there is a pressing need to shift toward dynamic RPP-guided hemodynamic strategies that can integrate real-time tissue perfusion monitoring to allow more individualized hemodynamic adjustments. Multimodal monitoring - using intrarenal Doppler imaging, contrast-enhanced ultrasound, urinary bladder oxygen sensors, microcirculatory imaging tools, tissue oxygenation monitoring, assessment of intra-renal pressure, and plasma and urinary biomarkers - can provide a real-time overview of adequacy of renal tissue perfusion. When integrated at the bedside, these technologies may detect hypoperfusion earlier, guide individualized RPP targets, and enable precision interventions tailored to patient-specific pathophysiology. However, though promising, the use of these novel tools is currently supported by only preliminary data and additional multicentre studies are required to better define and validate their use. In addition, future research should focus on defining personalized RPP thresholds, as optimal perfusion likely varies with comorbidities, baseline renal function, and the nature of critical illness. Machine learning models trained on multi-parametric data could assist in risk stratification and early warning of renal malperfusion. Additionally, much of the current literature focuses on short-term outcomes such as in-hospital AKI and mortality. However, the long-term consequences of sustained RPP derangements, including progression to chronic kidney disease and long-term dialysis dependence, remain underexplored. Prospective cohort studies with extended follow-up are essential to understanding the broader impact of RPP management during critical illness.

Acknowledgements

Not applicable.

Authors contribution

RP, BM, JPT, AK: Drafted this review and contributed to critical revision of the manuscript for important intellectual content.

Funding

No specific funding was received for the preparation of this review. RP is a recipient of NHMRC/MRFF Clinical Trials Activity grant (ID: 2022/MRF2019812) for a separate but related research project.

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors consent for the publication of this study report.

Competing interests

RP, BM and AK have no competing interests to declare. JPT reports ownership interest via publicly traded stock or stock options in Eli Lilly and Company, Novo Nordisk A/S, Pfizer Inc. and research funding (provided to his institution) from La Jolla Pharmaceutical Company/Innoviva for trial related to angiotensin II use (NCT05824767).

Received: 10 June 2025 / Accepted: 25 July 2025

Published online: 08 August 2025

References

1. Botti RE, Razzak MA, MacIntyre WJ, Pritchard WH. The relationship of renal blood flow to cardiac output in normal individuals as determined by concomitant radioisotopic measurements. *Cardiovasc Res* Jul. 1968;2(3):243–6. <https://doi.org/10.1093/cvr/2.3.243>.
2. Zafrani L, Ince C. Microcirculation in acute and chronic kidney diseases. *Am J Kidney Dis* Dec. 2015;66(6):1083–94. <https://doi.org/10.1053/j.ajkd.2015.06.019>.
3. Guerci P, Ergin B, Ince C. The macro- and microcirculation of the kidney. *Best Pract Res Clin Anaesthesiol* Sep. 2017;31(3):315–29. <https://doi.org/10.1016/j.bpa.2017.10.002>.
4. Marsh DJ, Wexler AS, Holstein-Rathlou NH. Interacting information streams on the nephron arterial network. *Front Netw Physiol*. 2023;3:1254964. <https://doi.org/10.3389/fnetp.2023.1254964>.
5. Nordsletten DA, Blackett S, Bentley MD, Ritman EL, Smith NP. Structural morphology of renal vasculature. *Am J Physiol Heart Circ Physiol*. Jul 2006;291(1):H296–309. <https://doi.org/10.1152/ajpheart.00814.2005>.
6. Schurek HJ, Jost U, Baumgärtl H, Bertram H, Heckmann U. Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. *Am J Physiol* Dec. 1990;259(6 Pt 2):F910–5. <https://doi.org/10.1152/ajprenal.1990.259.6.F910>.
7. Pallone TL, Edwards A, Mattson DL. Renal medullary circulation. *Compr Physiol* Jan. 2012;2(1):97–140. <https://doi.org/10.1002/cphy.c100036>.
8. Denic A, Lieske JC, Chakkera HA, et al. The substantial loss of nephrons in healthy human kidneys with aging. *J Am Soc Nephrol* Jan. 2017;28(1):313–20. <https://doi.org/10.1681/ASN.2016020154>.
9. Bertram JF, Douglas-Denton RN, Diouf B, Hughson MD, Hoy WE. Human nephron number: implications for health and disease. *Pediatr Nephrol* Sep. 2011;26(9):1529–33. <https://doi.org/10.1007/s00467-011-1843-8>.
10. Neuman J, Schulz L, Aneman A. Associations between mean systemic filling pressure and acute kidney injury: an observational cohort study following cardiac surgery. *Acta Anaesthesiol Scand* Mar. 2021;65(3):373–80. <https://doi.org/10.1111/aas.13732>.
11. Persichini R, Lai C, Teboul JL, Adda I, Guérin L, Monnet X. Venous return and mean systemic filling pressure: physiology and clinical applications. *Crit Care* May. 2022;24(1):150. <https://doi.org/10.1186/s13054-022-04024-x>.

12. Parkin WG, Leaning MS. Therapeutic control of the circulation. *J Clin Monit Comput Dec.* 2008;22(6):391–400. <https://doi.org/10.1007/s10877-008-9147-7>.
13. Wijnberge M, Sindhunata DP, Pinsky MR, et al. Estimating mean circulatory filling pressure in clinical practice: a systematic review comparing three bedside methods in the critically ill. *Ann Intensive Care Jun.* 2018;20(1):73. <https://doi.org/10.1186/s13613-018-0418-2>.
14. Blantz RC, Deng A, Miracle CM, Thomson SC. Regulation of kidney function and metabolism: a question of supply and demand. *Trans Am Clin Climatol Assoc.* 2007;118:23–43.
15. Sgouralis I, Layton AT. Mathematical modeling of renal hemodynamics in physiology and pathophysiology. *Math Biosci Jun.* 2015;264:8–20. <https://doi.org/10.1016/j.mbs.2015.02.016>.
16. Carlstrom M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease. *Physiol Rev Apr.* 2015;95(2):405–511. <https://doi.org/10.1152/physrev.00042.2012>.
17. Just A. Mechanisms of renal blood flow autoregulation: dynamics and contributions. *Am J Physiol Regul Integr Comp Physiol Jan.* 2007;292(1):R1–17. <http://doi.org/10.1152/ajpregu.00332.2006>.
18. Holstein-Rathlou NH, Marsh DJ. Renal blood flow regulation and arterial pressure fluctuations: a case study in nonlinear dynamics. *Physiol Rev Jul.* 1994;74(3):637–81. <https://doi.org/10.1152/physrev.1994.74.3.637>.
19. Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of Renin release. *J Am Soc Nephrol.* Jul 2010;21(7):1093–6. <https://doi.org/10.1681/ASN.2009070759>.
20. Schnermann J, Briggs JP. Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice. *Kidney Int Aug.* 2008;74(4):418–26. <https://doi.org/10.1038/ki.2008.145>.
21. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. *Physiol Rev Apr.* 1996;76(2):425–536. <https://doi.org/10.1152/physrev.1996.76.2.425>.
22. Edwards A, Kurtcuoglu V. Renal blood flow and oxygenation. *Pflugers Arch Aug.* 2022;474(8):759–70. <https://doi.org/10.1007/s00424-022-02690-y>.
23. Hoste EAJ, De laet IE. Renal blood flow regulation. In: Vincent J-L, Hall JB, editors. *Encyclopedia of intensive care medicine*. Berlin Heidelberg: Springer; 2012. pp. 1964–7.
24. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. *Am J Physiol.* Feb 1989;256(2 Pt 2):F274–8. <https://doi.org/10.1152/ajprenal.1989.256.2.F274>.
25. Di Giantomasso D, Morimatsu H, May CN, Bellomo R. Intrarenal blood flow distribution in hyperdynamic septic shock: effect of norepinephrine. *Crit Care Med.* Oct 2003;31(10):2509–13. <https://doi.org/10.1097/01.CCM.0000084842.66153.5A>.
26. Lankadeva YR, Kosaka J, Evans RG, Bailey SR, Bellomo R, May CN. Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury. *Kidney Int Jul.* 2016;90(1):100–8. <https://doi.org/10.1016/j.kint.2016.02.017>.
27. Albanese J, Leone M, Garnier F, Bourgoin A, Antonini F, Martin C. Renal effects of norepinephrine in septic and nonseptic patients. *Chest Aug.* 2004;126(2):534–9. <https://doi.org/10.1378/chest.126.2.534>.
28. Bellomo R, Kellum JA, Wisniewski SR, Pinsky MR. Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. *Am J Respir Crit Care Med.* Apr 1999;159(4 Pt 1):1186–92. <https://doi.org/10.1164/ajrccm.159.4.9802055>.
29. Martin C, Eon B, Saux P, Aknin P, Gouin F. Renal effects of norepinephrine used to treat septic shock patients. *Crit Care Med.* Mar 1990;18(3):282–5. <https://doi.org/10.1097/00003246-199003000-00007>.
30. Anderson WP, Korner PI, Selig SE. Mechanisms involved in the renal responses to intravenous and renal artery infusions of noradrenaline in conscious dogs. *J Physiol Dec.* 1981;321:21–30. <https://doi.org/10.1113/jphysiol.1981.sp013969>.
31. MOYER JM, HANDLEY CA. Norepinephrine and epinephrine effect on renal hemodynamics, with particular reference to the possibility of vascular shunting and decreasing the active glomeruli. *Circulation Jan.* 1952;5(1):91–7. <https://doi.org/10.1161/01.cir.5.1.91>.
32. Chawla LS. Permissive azotemia during acute kidney injury enables more rapid renal recovery and less renal fibrosis: a hypothesis and clinical development plan. *Crit Care Apr.* 2022;28(1):116. <https://doi.org/10.1186/s13054-022-03988-0>.
33. Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. *Shock Jan.* 2014;41(1):3–11. <https://doi.org/10.1097/SHK.0000000000000052>.
34. Redfors B, Bragadottir G, Sellgren J, Sward K, Ricksten SE. Acute renal failure is NOT an acute renal success—a clinical study on the renal oxygen supply/demand relationship in acute kidney injury. *Crit Care Med Aug.* 2010;38(8):1695–701. <https://doi.org/10.1097/CCM.0b013e3181e61911>.
35. Gumbert SD, Kork F, Jackson ML, et al. Perioperative acute kidney injury. *Anesthesiology Jan.* 2020;132(1):180–204. <https://doi.org/10.1097/ALN.0000000000002968>.
36. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. *Kidney Int Nov.* 2002;62(5):1539–49. <https://doi.org/10.1046/j.1523-1755.2002.00631.x>.
37. Myers BD, Deen WM, Robertson CR, Brenner BM. Dynamics of glomerular ultrafiltration in the rat. VIII. Effects of hematocrit. *Circ Res Mar.* 1975;36(3):425–35. <https://doi.org/10.1161/01.res.36.3.425>.
38. Hansell P, Welch WJ, Blantz RC, Palm F. Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension. *Clin Exp Pharmacol Physiol Feb.* 2013;40(2):123–37. <https://doi.org/10.1111/1440-1681.12034>.
39. Mandel LJ, Balaban RS. Stoichiometry and coupling of active transport to oxidative metabolism in epithelial tissues. *Am J Physiol.* May 1981;240(5):F357–71. <https://doi.org/10.1152/ajprenal.1981.240.5.F357>.
40. KILL F, AUKLAND K, REFSUM HE. Renal sodium transport and oxygen consumption. *Am J Physiol Sep.* 1961;201:511–6. <https://doi.org/10.1152/ajplegacy.1961.201.3.511>.
41. Takeuchi T, Flannery AH, Liu LJ, et al. Epidemiology of sepsis-associated acute kidney injury in the ICU with contemporary consensus definitions. *Crit Care Mar.* 2025;20(1):128. <https://doi.org/10.1186/s13054-025-05351-5>.
42. Monard C, Bianchi N, Kelevina T, Altarelli M, Schneider A. Epidemiology and outcomes of early versus late septic acute kidney injury in critically ill patients: A retrospective cohort study. *Anaesth Crit Care Pain Med.* Feb 2024;43(1):101332. <https://doi.org/10.1016/j.jaccpm.2023.101332>.
43. White KC, Serpa-Neto A, Hurford R, et al. Sepsis-associated acute kidney injury in the intensive care unit: incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes. A multicenter, observational study. *Intensive Care Med.* Sep 2023;49(9):1079–89. <https://doi.org/10.1007/s00134-023-07138-0>.
44. Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. *Clin J Am Soc Nephrol.* May 2007;2(3):431–9. <https://doi.org/10.2215/CJN.03681106>.
45. Prowle JR, Molan MP, Hornsey E, Bellomo R. Measurement of renal blood flow by phase-contrast magnetic resonance imaging during septic acute kidney injury: a pilot investigation. *Crit Care Med Jun.* 2012;40(6):1768–76. <https://doi.org/10.1097/CCM.0b013e318246bd85>.
46. Langenberg C, Gobe G, Hood S, May CN, Bellomo R. Renal histopathology during experimental septic acute kidney injury and recovery. *Crit Care Med Jan.* 2014;42(1):e58–67. <https://doi.org/10.1097/CCM.0b013e3182a639da>.
47. Fiorese Coimbra KT, de Freitas FGR, Bafi AT, et al. Effect of increasing blood pressure with noradrenaline on the microcirculation of patients with septic shock and previous arterial hypertension. *Crit Care Med Aug.* 2019;47(8):1033–40. <https://doi.org/10.1097/CCM.0000000000003795>.
48. Xu JY, Ma SQ, Pan C, et al. A high mean arterial pressure target is associated with improved microcirculation in septic shock patients with previous hypertension: a prospective open label study. *Crit Care Mar.* 2015;19:130. <https://doi.org/10.1186/s13054-015-0866-0>.
49. Legrand M, Bezemer R, Kandil A, Demirci C, Payen D, Ince C. The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats. *Intensive Care Med.* Sep 2011;37(9):1534–42. <https://doi.org/10.1007/s00134-011-2267-4>.
50. Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med Aug.* 2015;41(8):1411–23. <https://doi.org/10.1007/s00134-015-3934-7>.
51. Griffin BR, Liu KD, Teixeira JP. Critical care nephrology: core curriculum 2020. *Am J Kidney Dis Mar.* 2020;75(3):435–52. <https://doi.org/10.1053/j.ajkd.2019.10.010>.
52. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA Aug.* 2005;17(7):813–8. <https://doi.org/10.1001/jama.294.7.813>.
53. Trask-Marino AL, Marino B, Lancefield TF, et al. Renal macro- and microcirculatory perturbations in acute kidney injury and chronic kidney disease associated with heart failure and cardiac surgery. *Am J Physiol Ren Physiol Apr.* 2025;01(4):F452–69. <https://doi.org/10.1152/ajprenal.00266.2024>.

54. Herrler T, Tischer A, Meyer A, et al. The intrinsic renal compartment syndrome: new perspectives in kidney transplantation. *Transplantation Jan.* 2010;89(1):40–6. <https://doi.org/10.1097/TP.0b013e3181c40aba>.
55. Tanaka M, Yoshida H, Furuhashi M, et al. Deterioration of renal function by chronic heart failure is associated with congestion and oxidative stress in the tubulointerstitium. *Intern Med.* 2011;50(23):2877–87. <https://doi.org/10.2169/internalmedicine.50.5925>.
56. Nakano D, Kitada K, Wan N, et al. Lipopolysaccharide induces filtrate leakage from renal tubular lumina into the interstitial space via a proximal tubular Toll-like receptor 4-dependent pathway and limits sensitivity to fluid therapy in mice. *Kidney Int May.* 2020;97(5):904–12. <https://doi.org/10.1016/j.kint.2019.11.024>.
57. Rogers WK, Garcia L. Intraabdominal Hypertension. Abdominal compartment syndrome, and the open abdomen. *Chest Jan.* 2018;153(1):238–50. <https://doi.org/10.1016/j.chest.2017.07.023>.
58. Kirkpatrick AW, Roberts DJ, De Waele J, et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the world society of the abdominal compartment syndrome. *Intensive Care Med Jul.* 2013;39(7):1190–206. <https://doi.org/10.1007/s00134-013-2906-z>.
59. Bradley SE, Bradley GP. The effect of increased Intra-Abdominal pressure on renal function in man. *J Clin Invest Sep.* 1947;26(5):1010–22. <https://doi.org/10.1172/JCI101867>.
60. Pereira R, Buglevski M, Perdigoto R, et al. Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient: prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care. *PLoS ONE.* 2021;16(5):e0251498. <https://doi.org/10.1371/journal.pone.0251498>.
61. Umgelter A, Reindl W, Wagner KS, et al. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense Ascites and hepatorenal syndrome: a prospective uncontrolled trial. *Crit Care.* 2008;12(1):R4. <https://doi.org/10.1186/cc6765>.
62. Umgelter A, Reindl W, Franzen M, Lenhardt C, Huber W, Schmid RM. Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense Ascites. *Intensive Care Med Jan.* 2009;35(1):152–6. <https://doi.org/10.1007/s00134-008-1253-y>.
63. Vaughan ED, Sorenson EJ, Gillenwater JY. The renal hemodynamic response to chronic unilateral complete ureteral occlusion. *Invest Urol Jul.* 1970;8(1):78–90.
64. Douvris A, Zeid K, Hiremath S, et al. Mechanisms for hemodynamic instability related to renal replacement therapy: a narrative review. *Intensive Care Med.* Oct 2019;45(10):1333–46. <https://doi.org/10.1007/s00134-019-05707-w>.
65. Bagshaw SM, Wald R, Adhikari NKJ, et al. Timing of initiation of Renal-Replacement therapy in acute kidney injury. *N Engl J Med Jul.* 2020;16(3):240–51. <https://doi.org/10.1056/NEJMoa2000741>.
66. Shawwa K, Kompotiatis P, Jentzer JC, et al. Hypotension within one-hour from starting CRRT is associated with in-hospital mortality. *J Crit Care Dec.* 2019;54:7–13. <https://doi.org/10.1016/j.jccr.2019.07.004>.
67. Silversides JA, Pinto R, Kuint R, et al. Fluid balance, intradialytic hypotension, and outcomes in critically ill patients undergoing renal replacement therapy: a cohort study. *Crit Care Nov.* 2014;18(6):624. <https://doi.org/10.1186/s13054-014-0624-8>.
68. Bitker L, Bayle F, Yonis H, et al. Prevalence and risk factors of hypotension associated with pre-load-dependence during intermittent Hemodialysis in critically ill patients. *Crit Care Feb.* 2016;20:44. <https://doi.org/10.1186/s13054-016-1227-3>.
69. Mc Causland FR, Waikar SS. Association of predialysis calculated plasma osmolality with intradialytic blood pressure decline. *Am J Kidney Dis Sep.* 2015;66(3):499–506. <https://doi.org/10.1053/j.ajkd.2015.03.028>.
70. Larkin JW, Reviriego-Mendoza MM, Usvyat LA, Kotanko P, Maddux FW. To cool, or too cool: is reducing dialysate temperature the optimal approach to preventing intradialytic hypotension? *Semin Dial Nov.* 2017;30(6):501–8. <https://doi.org/10.1111/sdi.12628>.
71. Patel S, Raimann JG, Kotanko P. The impact of Dialysis modality and membrane characteristics on intradialytic hypotension. *Semin Dial Nov.* 2017;30(6):518–31. <https://doi.org/10.1111/sdi.12636>.
72. Stricker KH, Takala J, Hullin R, Ganter CC. When drugs disappear from the patient: elimination of intravenous medication by hemodiafiltration. *Anesth Analg Nov.* 2009;109(5):1640–3. <https://doi.org/10.1213/ANE.0b013e3181b9db63>.
73. McIntyre CW, Burton JO, Selby NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. *Clin J Am Soc Nephrol Jan.* 2008;3(1):19–26. <https://doi.org/10.2215/CJN.03170707>.
74. Mahmoud H, Forni LG, McIntyre CW, Selby NM. Myocardial stunning occurs during intermittent haemodialysis for acute kidney injury. *Intensive Care Med Jun.* 2017;43(6):942–4. <https://doi.org/10.1007/s00134-017-4768-2>.
75. Slessarev M, Salerno F, Ball IM, McIntyre CW. Continuous renal replacement therapy is associated with acute cardiac stunning in critically ill patients. *Hemodial Int Jul.* 2019;23(3):325–32. <https://doi.org/10.1111/hdi.12760>.
76. Krishnan S, Suarez-Martinez AD, Bagher P, et al. Microvascular dysfunction and kidney disease: challenges and opportunities? *Microcirculation Apr.* 2021;28(3):e12661. <https://doi.org/10.1111/micc.12661>.
77. Kotani Y, Chappell M, Landoni G, Zarbock A, Bellomo R, Khanna AK. Renin in critically ill patients. *Ann Intensive Care May.* 2024;22(1):79. <https://doi.org/10.1186/s13613-024-01304-3>.
78. Busse LW, Schaich CL, Chappell MC, et al. Association of active Renin content with mortality in critically ill patients: A post hoc analysis of the vitamin C, thiamine, and steroids in sepsis (VICTAS) trial. *Crit Care Med Mar.* 2024;01(3):441–51. <https://doi.org/10.1097/CCM.00000000000006095>.
79. Lešnik P, Lysenko L, Krzystek-Korpacka M, Woźnica-Niesobka E, Mierzczałka-Pasierb M, Janc J. Renin as a marker of tissue perfusion, septic shock and mortality in septic patients: A prospective observational study. *Int J Mol Sci Aug.* 2022;15(16). <https://doi.org/10.3390/ijms23169133>.
80. Lee GT, Ko BS, Kim DS, et al. Diagnostic accuracy of plasma Renin concentration and Renin activity in predicting mortality and kidney outcomes in patients with septic shock and hypoperfusion or hypotension: A multicenter, prospective, observational study. *Ann Lab Med Nov.* 2024;01(6):497–506. <https://doi.org/10.3343/alm.2023.0425>.
81. Flannery AH, Ortiz-Soriano V, Li X, et al. Serum Renin and major adverse kidney events in critically ill patients: a multicenter prospective study. *Crit Care Aug.* 2021;14(1):294. <https://doi.org/10.1186/s13054-021-03725-z>.
82. Gleeson PJ, Crippa IA, Mongkolpun W, et al. Renin as a marker of Tissue-Perfusion and prognosis in critically ill patients. *Crit Care Med Feb.* 2019;47(2):152–8. <https://doi.org/10.1097/CCM.00000000000003544>.
83. Jeyaraju M, McCurdy MT, Levine AR, et al. Renin kinetics are superior to lactate kinetics for predicting In-Hospital mortality in hypotensive critically ill patients. *Crit Care Med Jan.* 2022;01(1):50–60. <https://doi.org/10.1097/CCM.00000000000005143>.
84. Bellomo R, Forni LG, Busse LW, et al. Renin and survival in patients given angiotensin II for Catecholamine-Resistant vasodilatory shock. A clinical trial. *Am J Respir Crit Care Med Nov.* 2020;01(9):1253–61. <https://doi.org/10.1164/rccm.201911-2172OC>.
85. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated Lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol.* Oct 2003;14(10):2534–43. <https://doi.org/10.1097/01.asn.0000088027.54400.c6>.
86. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, Group NM-al. Accuracy of neutrophil gelatinase-associated Lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis Dec.* 2009;54(6):1012–24. <https://doi.org/10.1053/j.ajkd.2009.07.020>.
87. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. *J Am Coll Cardiol Apr.* 2011;26(17):1752–61. <https://doi.org/10.1016/j.jacc.2010.11.051>.
88. Nickolas TL, Schmidt-Ott KM, Canetta P, et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. *J Am Coll Cardiol.* Jan 2012;17(3):246–55. <https://doi.org/10.1016/j.jacc.2011.10.854>.
89. Boutin L, Latosinska A, Mischak H, et al. Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis. *Intensive Care Med.* Oct 2023;49(10):1191–202. <https://doi.org/10.1007/s00134-023-07198-2>.
90. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. *Crit Care Feb.* 2013;06(1):R25. <https://doi.org/10.1186/cc12503>.
91. Huang F, Zeng Y, Lv L, et al. Predictive value of urinary cell cycle arrest biomarkers for all cause-acute kidney injury: a meta-analysis. *Sci Rep Apr.* 2023;13(1):6037. <https://doi.org/10.1038/s41598-023-33233-9>.
92. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients

- identified by biomarkers: the PrevAKI randomized controlled trial. *Intensive Care Med* Nov. 2017;43(11):1551–61. <https://doi.org/10.1007/s00134-016-4670-3>.
93. Göcçe I, Jauch D, Götz M, et al. Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigPAK study. *Ann Surg Jun*. 2018;267(6):1013–20. <https://doi.org/10.1097/SLA.0000000000002485>.
94. Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel Immunoglobulin domain, is up-regulated in renal cells after injury. *J Biol Chem Feb*. 1998;13(7):4135–42. <https://doi.org/10.1074/jbc.273.7.4135>.
95. Ichimura T, Asselton EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. *J Clin Invest May*. 2008;118(5):1657–68. <https://doi.org/10.1172/JCI34487>.
96. Basu RK, Wang Y, Wong HR, Chawla LS, Wheeler DS, Goldstein SL. Incorporation of biomarkers with the renal angina index for prediction of severe AKI in critically ill children. *Clin J Am Soc Nephrol Apr*. 2014;9(4):654–62. <https://doi.org/10.2215/CJN.09720913>.
97. Matsuura R, Srisawat N, Claire-Del Granado R, et al. Use of the renal angina index in determining acute kidney injury. *Kidney Int Rep May*. 2018;3(3):677–83. <https://doi.org/10.1016/j.ekir.2018.01.013>.
98. Goldstein SL, Krallman KA, Roy JP, et al. Real-Time acute kidney injury risk Stratification-Biomarker directed fluid management improves outcomes in critically ill children and young adults. *Kidney Int Rep Dec*. 2023;8(12):2690–700. <https://doi.org/10.1016/j.ekir.2023.09.019>.
99. Qian X, Zhen J, Meng Q, Li L, Yan J. Intrarenal doppler approaches in hemodynamics: A major application in critical care. *Front Physiol*. 2022;13:951307. <https://doi.org/10.3389/fphys.2022.951307>.
100. Rozemeijer S, Haltsma Mulier JLG, Röttgering JG, et al. Renal resistive index: response to shock and its determinants in critically ill patients. *Shock Jul*. 2019;52(1):43–51. <https://doi.org/10.1097/SHK.00000000000001246>.
101. Di Nicolò P, Granata A. Renal intraparenchymal resistive index: the ultrasonographic answer to many clinical questions. *J Nephrol Aug*. 2019;32(4):527–38. <https://doi.org/10.1007/s40620-018-00567-x>.
102. Tublin ME, Bude RO, Platt JF. Review. The resistive index in renal doppler sonography: where do we stand? *AJR Am J Roentgenol Apr*. 2003;180(4):885–92. <https://doi.org/10.2214/ajr.180.4.1800885>.
103. Darmon M, Bourmaud A, Reynaud M, et al. Performance of Doppler-based resistive index and semi-quantitative renal perfusion in predicting persistent AKI: results of a prospective multicenter study. *Intensive Care Med Nov*. 2018;44(11):1904–13. <https://doi.org/10.1007/s00134-018-5386-3>.
104. Husain-Syed F, Gröne HJ, Assmus B, et al. Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. *ESC Heart Fail Feb*. 2021;8(1):183–203. <https://doi.org/10.1002/ehf2.13118>.
105. Iida N, Seo Y, Sai S, et al. Clinical implications of intrarenal hemodynamic evaluation by doppler ultrasonography in heart failure. *JACC Heart Fail Aug*. 2016;4(8):674–82. <https://doi.org/10.1016/j.jchf.2016.03.016>.
106. Beaubien-Souligny W, Rola P, Haycock K, et al. Quantifying systemic congestion with Point-Of-Care ultrasound: development of the venous excess ultrasound grading system. *Ultrasound J Apr*. 2020;09(1):16. <https://doi.org/10.1186/s13089-020-00163-w>.
107. Spiegel R, Teeter W, Sullivan S, et al. The use of venous doppler to predict adverse kidney events in a general ICU cohort. *Crit Care Oct*. 2020;19(1):615. <https://doi.org/10.1186/s13054-020-03330-6>.
108. Guinot PG, Bahr PA, Andrei S, et al. Doppler study of portal vein and renal venous velocity predict the appropriate fluid response to diuretic in ICU: a prospective observational echocardiographic evaluation. *Crit Care Oct*. 2022;05(1):305. <https://doi.org/10.1186/s13054-022-04180-0>.
109. Teixeira JP, Zeidman A, Beaubien-Souligny W et al. Proceedings of the 2022 UAB CRRT Academy: Non-Invasive Hemodynamic Monitoring to Guide Fluid Removal with CRRT and Proliferation of Extracorporeal Blood Purification Devices. *Blood Purif*. 2023;52(11–12):857–879. <https://doi.org/10.1159/000533573>.
110. Chen R, Gao B, Wang X, Zhao H, Liu D. Ultrasonographic assessment of renal microcirculation is a new vision for the treatment of intensive care unit associated acute kidney injury. *Eur J Med Res Feb*. 2024;10(1):115. <https://doi.org/10.1186/s40001-024-01704-y>.
111. Tranquart F, Mercier L, Frinking P, Gaud E, Arditi M. Perfusion quantification in contrast-enhanced ultrasound (CEUS)—ready for research projects and routine clinical use. *Ultraschall Med Jul*. 2012;33(Suppl 1):S31–8. <https://doi.org/10.1055/s-0032-1312894>.
112. Yoon HE, Kim DW, Kim D, Kim Y, Shin SJ, Shin YR. A pilot trial to evaluate the clinical usefulness of contrast-enhanced ultrasound in predicting renal outcomes in patients with acute kidney injury. *PLoS ONE*. 2020;15(6):e0235130. <https://doi.org/10.1371/journal.pone.0235130>.
113. Schneider AG, Goodwin MD, Schelleman A, Bailey M, Johnson L, Bellomo R. Contrast-enhanced ultrasound to evaluate changes in renal cortical perfusion around cardiac surgery: a pilot study. *Crit Care Jul*. 2013;12(4):R138. <https://doi.org/10.1186/cc12817>.
114. Schneider AG, Goodwin MD, Schelleman A, Bailey M, Johnson L, Bellomo R. Contrast-enhanced ultrasonography to evaluate changes in renal cortical microcirculation induced by noradrenaline: a pilot study. *Crit Care Dec*. 2014;02(6):653. <https://doi.org/10.1186/s13054-014-0653-3>.
115. Murkin JM, Arango M. Near-infrared spectroscopy as an index of brain and tissue oxygenation. *Br J Anaesth Dec*. 2009;103(Suppl 1):i3–13. <https://doi.org/10.1093/bja/aep299>.
116. Delrue C, De Bruyne S, Speckaert MM. The potential use of Near- and Mid-Infrared spectroscopy in kidney diseases. *Int J Mol Sci Apr*. 2023;04(7). <https://doi.org/10.3390/ijms24076740>.
117. Liu C, Wang X, Shi W, et al. The relationship between trajectories of renal oxygen saturation and acute kidney injury: a prospective cohort study with a secondary analysis. *Aging Clin Exp Res Feb*. 2024;21(1):46. <https://doi.org/10.1007/s40520-024-02701-1>.
118. Hu RT, Lankadeva YR, Yanase F, Osawa EA, Evans RG, Bellomo R. Continuous bladder urinary oxygen tension as a new tool to monitor medullary oxygenation in the critically ill. *Crit Care Dec*. 2022;16(1):389. <https://doi.org/10.1186/s13054-022-04230-7>.
119. LEONHARDT KO, LANDES RR. Oxygen tension of the urine and renal structures. Preliminary report of clinical findings. *N Engl J Med Jul*. 1963;18:269:115–21. <https://doi.org/10.1056/NEJM196307182690301>.
120. Lankadeva YR, Cochrane AD, Marino B, et al. Strategies that improve renal medullary oxygenation during experimental cardiopulmonary bypass May mitigate postoperative acute kidney injury. *Kidney Int Jun*. 2019;95(6):1338–46. <https://doi.org/10.1016/j.kint.2019.01.032>.
121. Silverton NA, Lofgren LR, Hall IE, et al. Noninvasive urine oxygen monitoring and the risk of acute kidney injury in cardiac surgery. *Anesthesiology Sep*. 2021;01(3):406–18. <https://doi.org/10.1097/ALN.0000000000003663>.
122. Hu R, Yanase F, McCall P, Evans R, Raman J, Bellomo R. The effects of targeted changes in systemic blood flow and mean arterial pressure on urine oximetry during cardiopulmonary bypass. *J Cardiothorac Vasc Anesth Sep*. 2022;36(9):3551–60. <https://doi.org/10.1053/j.jvca.2022.05.023>.
123. Post EH, Vincent JL. Renal autoregulation and blood pressure management in circulatory shock. *Crit Care Mar*. 2018;22(1):81. <https://doi.org/10.1186/s13054-018-1962-8>.
124. Panwar R. Untreated relative hypotension measured as perfusion pressure deficit during management of shock and new-onset acute kidney injury: a literature review. *Rev Shock J May*. 2018;2017;49(5):497–507. <https://doi.org/10.1097/shk.0000000000001033>.
125. Ono M, Arnaoutakis GJ, Fine DM, et al. Blood pressure excursions below the cerebral autoregulation threshold during cardiac surgery are associated with acute kidney injury. *Crit Care Med Feb*. 2013;41(2):464–71. <https://doi.org/10.1097/CCM.0b013e31826ab3a1>.
126. Malbrain MLNG, De Keulenaer BL, Khanna AK. Continuous intra-abdominal pressure: is it ready for prime time? *Intensive Care Med Oct*. 2022;48(10):1501–4. <https://doi.org/10.1007/s00134-022-06780-4>.
127. Poukkanen M, Wilkman E, Vaara ST, et al. Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study. *Crit Care Dec*. 2013;13(6):R295. <https://doi.org/10.1186/cc13161>.
128. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock. Comparative study multicenter study randomized controlled trial research support, Non-U.S. Gov't. *N Engl J Med Apr*. 2014;24(17):1583–93. <https://doi.org/10.1056/NEJMoa1312173>.
129. Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-Day mortality in older critically ill patients with vasodilatory hypotension: A randomized clinical trial. *JAMA Feb*. 2020. <https://doi.org/10.1001/jama.2020.0930>.
130. Endo A, Yamakawa K, Tagami T, et al. Efficacy of targeting high mean arterial pressure for older patients with septic shock (OPTPRESS): a multicentre, pragmatic, open-label, randomised controlled trial. *Intensive Care Med May*. 2025;13. <https://doi.org/10.1007/s00134-025-07910-4>.
131. Groups P-TIS. A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a

- hypertension-avoidance strategy on the risk of acute kidney injury. *Kidney Int J*. 2025;107(1):155–68. <https://doi.org/10.1016/j.kint.2024.10.007>.
132. Tiruvoipati R, Kansal A, Panwar R. High mean arterial pressure (MAP) targets in septic shock: one size does not fit all. *Intensive Care Med* Jun. 2025;10. <https://doi.org/10.1007/s00134-025-07983-1>.
133. Panwar R. Untreated relative hypotension measured as perfusion pressure deficit during management of shock and New-Onset acute kidney injury-A literature review. *Shock* May. 2018;49(5):497–507. <https://doi.org/10.1097/SHK.0000000000001033>.
134. Panwar R, Tarvade S, Lanyon N, et al. Relative hypotension and adverse Kidney-related outcomes among critically ill patients with shock. A multicenter, prospective cohort study. *Am J Respir Crit Care Med*. 2020;11 15(10):1407–18. <https://doi.org/10.1164/rccm.201912-2316OC>.
135. Panwar R, Van Haren F, Cazzola F, Nourse M, Brinkerhoff G, Quail A. Standard care versus individualized blood pressure targets among critically ill patients with shock: A multicenter feasibility and preliminary efficacy study. *J Crit Care* May. 2022;04:70:154052. <https://doi.org/10.1016/j.jcrrc.2022.154052>.
136. Panwar R, McNicholas B, Nita C, et al. A pilot multicenter randomized controlled trial on individualized blood pressure targets versus standard care among critically ill patients with shock. *J Intensive Care* May. 2025;27(1):29. <https://doi.org/10.1186/s40560-025-00798-8>.
137. Futier E, Lefrant JY, Guinot PG, et al. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among High-Risk patients undergoing major surgery: A randomized clinical trial. *JAMA* Oct. 2017;10(14):1346–57. <https://doi.org/10.1001/jama.2017.14172>.
138. Li L, Qin S, Lu X, Huang L, Xie M, Huang D. Association between the mean perfusion pressure and the risk of acute kidney injury in critically ill patients with sepsis: a retrospective cohort study. *BMC Infect Dis* Aug. 2024;09(1):806. <https://doi.org/10.1186/s12879-024-09706-1>.
139. Ostermann M, Hall A, Crichton S. Low mean perfusion pressure is a risk factor for progression of acute kidney injury in critically ill patients - A retrospective analysis. *BMC Nephrol*. May 2017;3(1):151. <https://doi.org/10.1186/s12882-017-0568-8>.
140. Fang Y, Dou A, Xie H, et al. Association between renal mean perfusion pressure and prognosis in patients with sepsis-associated acute kidney injury: insights from the MIMIC IV database. *Ren Fail* Dec. 2025;47(1):2449579. <https://doi.org/10.1080/0886022X.2025.2449579>.
141. Panwar R, Lanyon N, Davies AR, Bailey M, Pilcher D, Bellomo R. Mean perfusion pressure deficit during the initial management of shock—an observational cohort study. *J Crit Care* Oct. 2013;28(5):816–24. <https://doi.org/10.1016/j.jcrrc.2013.05.009>.
142. Wong BT, Chan MJ, Glassford NJ, et al. Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury. *J Crit Care* Oct. 2015;30(5):975–81. <https://doi.org/10.1016/j.jcrrc.2015.05.003>.
143. Saito S, Uchino S, Takinami M, Uezono S, Bellomo R. Postoperative blood pressure deficit and acute kidney injury progression in vasopressor-dependent cardiovascular surgery patients. *Crit Care*. 2016;20(1):74. <https://doi.org/10.1186/s13054-016-1253-1>.
144. Kotani Y, Yoshida T, Kumasawa J, et al. The impact of relative hypotension on acute kidney injury progression after cardiac surgery: a multicenter retrospective cohort study. *Ann Intensive Care* Dec. 2021;20(1):178. <https://doi.org/10.1186/s13613-021-00969-4>.
145. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *J Am Coll Cardiol*. Feb 2009;53(7):589–96. <https://doi.org/10.1016/j.jacc.2008.05.068>.
146. Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. *Kidney Int* Aug. 2009;76(4):422–7. <https://doi.org/10.1038/ki.2009.159>.
147. Wang N, Jiang L, Zhu B, Wen Y, Xi XM, Workgroup BAKITB. Fluid balance and mortality in critically ill patients with acute kidney injury: a multicenter prospective epidemiological study. *Crit Care* Oct. 2015;23:19371. <https://doi.org/10.1186/s13054-015-1085-4>.
148. Meyhoff TS, Møller MH, Hjortrup PB, Cronhjort M, Perner A, Wetterslev J. Lower vs higher fluid volumes during initial management of sepsis: A systematic review with Meta-Analysis and trial sequential analysis. *Chest* Jun. 2020;157(6):1478–96. <https://doi.org/10.1016/j.chest.2019.11.050>.
149. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med*. Jun 2006;354(24):2564–75. <https://doi.org/10.1056/NEJMoa062200>.
150. Shapiro NI, Douglas IS, Brower RG, et al. Early restrictive or Liberal fluid management for Sepsis-Induced hypotension. *N Engl J Med* Feb. 2023;09(6):499–510. <https://doi.org/10.1056/NEJMoa2212663>.
151. Meyhoff TS, Hjortrup PB, Wetterslev J, et al. Restriction of intravenous fluid in ICU patients with septic shock. *N Engl J Med* Jun. 2022;30(26):2459–70. <https://doi.org/10.1056/NEJMoa2202707>.
152. Myles PS, Bellomo R, Corcoran T, et al. Restrictive versus Liberal fluid therapy for major abdominal surgery. *N Engl J Med* Jun. 2018;14(24):2263–74. <https://doi.org/10.1056/NEJMoa1801601>.
153. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Crit Care Med*. 2021;11 01(11):e1063–143. <https://doi.org/10.1097/CCM.0000000000000537>.
154. Wilcox CS. Regulation of renal blood flow by plasma chloride. *J Clin Invest* Mar. 1983;71(3):726–35. <https://doi.org/10.1172/jci110820>.
155. Yunus NM, Bellomo R, Glassford N, Sutcliffe H, Lam Q, Bailey M. Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis. *Intensive Care Med*. Feb 2015;41(2):257–64. <http://doi.org/10.1007/s00134-014-3593-0>.
156. Young P, Bailey M, Beasley R, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. *JAMA* Oct. 2015;27(16):1701–10. <https://doi.org/10.1001/jama.2015.12334>.
157. Finfer S, Micallef S, Hammond N, et al. Balanced multielectrolyte solution versus saline in critically ill adults. *N Engl J Med* Mar. 2022;03(9):815–26. <https://doi.org/10.1056/NEJMoa2114464>.
158. Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. *N Engl J Med*. 2018;03 01(9):829–39. <https://doi.org/10.1056/NEJMoa1711584>.
159. Hammond NE, Zampieri FG, Di Tanna GL, et al. Balanced crystalloids versus saline in critically ill Adults - A systematic review with Meta-Analysis. *NEJM Evid* Feb. 2022;1(2):EVIDoa2100010. <https://doi.org/10.1056/EVIDoa2100010>.
160. Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. *Crit Care Med*. Apr 2008;36(4 Suppl):S179–86. <https://doi.org/10.1097/CCM.0b013e318169167f>.
161. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* Feb. 2008;358(9):877–87. <http://doi.org/10.1056/NEJMoa067373>.
162. Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. *Intensive Care Med* Jan. 2010;36(1):83–91. <https://doi.org/10.1007/s00134-009-1687-x>.
163. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. *JAMA* Aug. 2016;02(5):509–18. <https://doi.org/10.1001/jama.2016.10485>.
164. Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCIS randomized controlled trial. *Anesthesiology* Jan. 2017;126(1):85–93. <https://doi.org/10.1097/ALN.0000000000001434>.
165. Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. *Crit Care Med* Jun. 2018;46(6):949–57. <https://doi.org/10.1097/CCM.0000000000003092>.
166. Chaba A, Zarbock A, Forni LG, CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY, et al. A POST HOC ANALYSIS OF THE ATHOS-3 TRIAL. *Shock* Jan. 2025;01(1):88–93. <https://doi.org/10.1097/SHK.0000000000002481>.
167. Okazaki N, Iguchi N, Evans RG, et al. Beneficial effects of vasopressin compared with norepinephrine on renal perfusion, oxygenation, and function in experimental septic acute kidney injury. *Crit Care Med*. Oct 2020;48(10):e951–8. <https://doi.org/10.1097/CCM.0000000000004511>.
168. Lankadeva YR, Kosaka J, Evans RG, Bellomo R, May CN. Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury. *Crit Care Med*. Jan 2018;46(1):e41–8. <https://doi.org/10.1097/CCM.0000000000002797>.
169. Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. *Intensive Care Med* Jun. 2019;45(6):844–55. <https://doi.org/10.1007/s00134-019-0562-0>.
170. Sacha GL, Lam SW, Wang L, Duggal A, Reddy AJ, Bauer SR. Association of catecholamine dose, lactate, and shock duration at vasopressin initiation with mortality in patients with septic shock. *Crit Care Med* Apr. 2022;01(4):614–23. <https://doi.org/10.1097/CCM.0000000000005317>.

171. Kotani Y, Belletti A, D'Amico F, et al. Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials. *Crit Care Dec.* 2024;30(1):439. <https://doi.org/10.1186/s13054-024-05212-7>.
172. Barbar SD, Clere-Jehl R, Bourredjem A, et al. Timing of Renal-Replacement therapy in patients with acute kidney injury and sepsis. *N Engl J Med.* Oct 2018;11(15):1431–42. <https://doi.org/10.1056/NEJMoa1803213>.
173. Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for Renal-Replacement therapy in the intensive care unit. *N Engl J Med.* Jul. 2016;14(2):122–33. <https://doi.org/10.1056/NEJMoa1603017>.
174. Bove T, Zangrillo A, Guarracino F, et al. Effect of Fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. *JAMA.* Dec. 2014;30(21):2244–53. <https://doi.org/10.1001/jama.2014.13573>.
175. Xiong B, Wang C, Yao Y, et al. The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials. *PLoS ONE.* 2015;10(6):e0131326. <https://doi.org/10.1371/journal.pone.0131326>.
176. Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. *N Engl J Med.* Oct. 2016;27(17):1638–48. <https://doi.org/10.1056/NEJMoa1609409>.
177. Zheng F, Wang YL, Zhou WY, et al. Continuous renal replacement therapy with adsorbing filter oXiris in the treatment of sepsis associated acute kidney injury: a single-center retrospective observational study. *BMC Nephrol.* Dec. 2024;18(1):456. <https://doi.org/10.1186/s12882-024-03897-0>.
178. Bajwa A, Kinsey GR, Okusa MD. Immune mechanisms and novel Pharmacological therapies of acute kidney injury. *Curr Drug Targets.* Dec. 2009;10(12):1196–204. <https://doi.org/10.2174/138945009789753174>.
179. Pickkers P, Mehta RL, Murray PT, et al. Effect of human Recombinant alkaline phosphatase on 7-Day creatinine clearance in patients with Sepsis-Associated acute kidney injury: A randomized clinical trial. *JAMA.* Nov. 2018;320(19):1998–2009. <https://doi.org/10.1001/jama.2018.14283>.
180. Pickkers P, Angus DC, Bass K, et al. Phase-3 trial of Recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL). *Intensive Care Med.* Jan. 2024;50(1):68–78. <https://doi.org/10.1007/s00134-023-07271-w>.
181. Gaudry S, Grolleau F, Barbar S, et al. Continuous renal replacement therapy versus intermittent Hemodialysis as first modality for renal replacement therapy in severe acute kidney injury: a secondary analysis of AKIKI and IDEAL-ICU studies. *Crit Care.* Apr. 2022;24(1):93. <https://doi.org/10.1186/s13054-022-03955-9>.
182. Wald R, Gaudry S, da Costa BR, et al. Initiation of continuous renal replacement therapy versus intermittent Hemodialysis in critically ill patients with severe acute kidney injury: a secondary analysis of STARTR-AKI trial. *Intensive Care Med.* Nov. 2023;49(11):1305–16. <https://doi.org/10.1007/s00134-023-07211-8>.
183. Wang Y, Gallagher M, Li Q, et al. Renal replacement therapy intensity for acute kidney injury and recovery to Dialysis independence: a systematic review and individual patient data meta-analysis. *Nephrol Dial Transplant.* Jun. 2018;33(6):1017–24. <https://doi.org/10.1093/ndt/gfx308>.
184. Murugan R, Kerti SJ, Chang CH, et al. Association of net ultrafiltration rate with mortality among critically ill adults with acute kidney injury receiving continuous venovenous hemodiafiltration: A secondary analysis of the randomized evaluation of normal vs augmented level (RENAL) of renal replacement therapy trial. *JAMA Netw Open.* Jun. 2019;2(6):e195418. <https://doi.org/10.1001/jamanetworkopen.2019.5418>.
185. Murugan R, Balakumar V, Kerti SJ, et al. Net ultrafiltration intensity and mortality in critically ill patients with fluid overload. *Crit Care.* Sep. 2018;22(9):e223. <https://doi.org/10.1186/s13054-018-2163-1>.
186. Bagshaw SM, Neto AS, Smith O, et al. Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARTR-AKI trial. *Intensive Care Med.* Dec. 2022;48(12):1736–50. <https://doi.org/10.1007/s00134-022-06912-w>.
187. Stoppe C, McDonald B, Meybohm P, et al. Effect of High-Dose selenium on postoperative organ dysfunction and mortality in cardiac surgery patients: the SUSTAIN CSX randomized clinical trial. *JAMA Surg.* Mar. 2023;158(3):235–44. <https://doi.org/10.1001/jamasurg.2022.6855>.
188. Fujii T, Luethi N, Young PJ, et al. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. *JAMA.* Feb. 2020;323(5):423–31. <https://doi.org/10.1001/jama.2019.22176>.
189. Sevransky JE, Rothman RE, Hager DN, et al. Effect of vitamin C, thiamine, and hydrocortisone on Ventilator- and Vasopressor-Free days in patients with sepsis: the VICTAS randomized clinical trial. *JAMA.* Feb. 2021;323(8):742–50. <https://doi.org/10.1001/jama.2020.24505>.
190. Lamontagne F, Masse MH, Menard J, et al. Intravenous vitamin C in adults with sepsis in the intensive care unit. *N Engl J Med.* Jun. 2022;386(25):2387–98. <https://doi.org/10.1056/NEJMoa2200644>.
191. Meyer TW, Ichikawa I, Zatz R, Brenner BM. The renal hemodynamic response to amino acid infusion in the rat. *Trans Assoc Am Physicians.* 1983;96:76–83.
192. Tolins JP, Shultz PJ, Westberg G, Raij L. Renal hemodynamic effects of dietary protein in the rat: role of nitric oxide. *J Lab Clin Med.* Feb. 1995;125(2):228–36.
193. Yao B, Xu J, Qi Z, Harris RC, Zhang MZ. Role of renal cortical cyclooxygenase-2 expression in hyperfiltration in rats with high-protein intake. *Am J Physiol Ren Physiol.* Aug. 2006;291(2):F368–74. <https://doi.org/10.1152/ajprenal.00500.2005>.
194. Jufar AH, Evans RG, May CN, et al. The effects of recruitment of renal functional reserve on renal cortical and medullary oxygenation in non-anesthetized sheep. *Acta Physiol (Oxf).* Apr. 2023;237(4):e13919. <https://doi.org/10.1111/apha.13919>.
195. Landoni G, Monaco F, Ti LK, et al. A randomized trial of intravenous amino acids for kidney protection. *N Engl J Med.* Aug. 2024;390(8):687–98. <https://doi.org/10.1056/NEJMoa2403769>.
196. Ostermann M, Shaw AD. Amino acid infusion to protect kidney function after cardiac surgery. *N Engl J Med.* Aug. 2024;390(8):759–60. <https://doi.org/10.1056/NEJMe2408632>.
197. Jiang W, Shi K, Shao J, et al. Protective effect of intravenous amino acid on kidney function: A systematic review and meta-analysis of randomized controlled trials. *J Crit Care.* Feb. 2025;85:154937. <https://doi.org/10.1016/j.jccr.2024.154937>.
198. Pruna A, Losiggio R, Landoni G, et al. Amino acid infusion for perioperative functional renal protection: A Meta-analysis. *J Cardiothorac Vasc Anesth.* Dec. 2024;38(12):3076–85. <https://doi.org/10.1053/j.jvca.2024.08.033>.
199. Doig GS, Simpson F, Bellomo R, et al. Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. *Intensive Care Med.* Jul. 2015;41(7):1197–208. <https://doi.org/10.1007/s00134-015-3827-9>.
200. Abuelo JG. Normotensive ischemic acute renal failure. *N Engl J Med.* Aug. 2007;357(8):797–805. <https://doi.org/10.1056/NEJMra064398>.
201. Deniau B, Blet A, Santos K, et al. Inhibition of Circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study. *PLoS ONE.* 2020;15(8):e0238039. <https://doi.org/10.1371/journal.pone.0238039>.
202. Picod A, Deniau B, Vaittinada Ayar P, et al. Alteration of the Renin-Angiotensin-Aldosterone system in shock: role of the dipeptidyl peptidase 3. *Am J Respir Crit Care Med.* Feb. 2021;203(4):526–7. <https://doi.org/10.1164/rccm.202010-3873LE>.
203. Corrêa TD, Takala J, Jakob SM. Angiotensin II in septic shock. *Crit Care.* Mar. 2015;19(3):e198. <https://doi.org/10.1186/s13054-015-0802-3>.
204. Rosa RM, Colucci JA, Yokota R, et al. Alternative pathways for angiotensin II production as an important determinant of kidney damage in endotoxemia. *Am J Physiol Ren Physiol.* Sep. 2016;302(3):F496–504. <https://doi.org/10.1152/ajprenal.00121.2014>.
205. Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A. Downregulation of angiotensin II type 1 receptors during sepsis. *Hypertension.* Aug. 2001;38(2):177–82. <https://doi.org/10.1161/01.hyp.38.2.177>.
206. Corrêa TD, Jeger V, Pereira AJ, Takala J, Djafarzadeh S, Jakob SM. Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a Porcine model of fecal peritonitis. *Crit Care Med.* Aug. 2014;42(8):e550–9. <https://doi.org/10.1097/CCM.0000000000000397>.
207. Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. *N Engl J Med.* May 2017. <https://doi.org/10.1056/NEJMoa1704154>.
208. García B, Zarbock A, Bellomo R, Legrand M. The alternative renin-angiotensin system in critically ill patients: pathophysiology and therapeutic implications. *Crit Care.* Nov. 2023;27(11):e453. <https://doi.org/10.1186/s13054-023-04739-5>.
209. Zaman A, Bandy AA. Angiotensin (1–7) protects against renal ischemia-reperfusion injury via regulating expression of Nrf2 and MicroRNAs in fisher 344 rats. *Am J Physiol Ren Physiol.* Jul. 2022;313(1):F33–47. <https://doi.org/10.1152/ajprenal.00283.2021>.
210. Ali R, Patel S, Hussain T. Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of

- renal ischemia. *Am J Physiol Ren Physiol* May. 2021;01(5):F814–25. <https://doi.org/10.1152/ajprenal.00507.2020>.
211. Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. *Physiol Rev* Jul. 2006;86(3):901–40. <https://doi.org/10.1152/physrev.00031.2005>.
212. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. *Arch Intern Med*. May 2005;23(10):1087–93. <https://doi.org/10.1001/archinte.165.10.1087>.
213. Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C. Effect of Theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. *Am J Kidney Dis* Sep. 2012;60(3):360–70. <https://doi.org/10.1053/jajkd.2012.02.332>.
214. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist Rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled randomized study of the selective adenosine A1 receptor antagonist Rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal Function). *J Am Coll Cardiol*. May 2011;10(19):1899–907. <https://doi.org/10.1016/j.jacc.2010.11.057>.
215. Chvojka J, Sykora R, Krouzecky A, et al. Renal haemodynamic, microcirculatory, metabolic and histopathological responses to peritonitis-induced septic shock in pigs. *Crit Care*. 2008;12(6):R164. <https://doi.org/10.1186/cc7164>.
216. Vellinga NA, Ince C, Boerma EC. Elevated central venous pressure is associated with impairment of microcirculatory blood flow in sepsis: a hypothesis generating post hoc analysis. *BMC Anesthesiol*. 2013;13:17. <https://doi.org/10.1186/1471-2253-13-17>.
217. Zarbock A, Küllmar M, Ostermann M, et al. Prevention of cardiac Surgery-Associated acute kidney injury by implementing the KDIGO guidelines in High-Risk patients identified by biomarkers: the PrevAKI-Multicenter randomized controlled trial. *Anesth Analg* Aug. 2021;01(2):292–302. <https://doi.org/10.1213/ANE.00000000000005458>.
218. Joannidis M, Druml W, Forni LG, et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: expert opinion of the working group on prevention, AKI section, European society of intensive care medicine. *Intensive Care Med* Jun. 2017;43(6):730–49. <https://doi.org/10.1007/s00134-017-4832-y>.
219. Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. *Lancet* May 24. 2014;383(9931):1814–23. [https://doi.org/10.1016/S0140-6736\(14\)60689-9](https://doi.org/10.1016/S0140-6736(14)60689-9).
220. Chirinos JA, Segers P, Hughes T, Townsend R. Large-Artery stiffness in health and disease: JACC State-of-the-Art review. *J Am Coll Cardiol*. Sep 2019;03(9):1237–63. <https://doi.org/10.1016/j.jacc.2019.07.012>.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.